Search results
Results from the WOW.Com Content Network
This form of medication helps in bone strength; however, it can have multiple side effects. In several reports, successful treatment with glucocorticosteroids was described, as certain side effects can benefit a person with CED. This drug helps with pain and fatigue as well as some correction of radiographic abnormalities. [16]
Osteolytic lesion at the bottom of the radius, diagnosed by a darker section that indicates a loss of bone density. An osteolytic lesion (from the Greek words for "bone" (ὀστέον), and "to unbind" (λύειν)) is a softened section of a patient's bone formed as a symptom of specific diseases, including breast cancer and multiple myeloma.
The diaphysis (pl.: diaphyses) is the main or midsection (shaft) of a long bone. It is made up of cortical bone and usually contains bone marrow and adipose tissue (fat). It is a middle tubular part composed of compact bone which surrounds a central marrow cavity which contains red or yellow marrow. In diaphysis, primary ossification occurs.
Osteolysis has been reported to occur as early as 12 months after implantation and is usually progressive. This may require a revision surgery (replacement of the prosthesis). [citation needed] Although osteolysis itself is clinically asymptomatic, it can lead to implant loosening or bone breakage, which in turn causes serious medical problems. [2]
Some side effects are specific to the anticancer drug used, the most common being bone marrow suppression as bone marrow has the ability to divide rapidly due to high growth fraction. [23] This is because anticancer drugs have the highest activity in high growth fraction tissues. [23]
Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [11] [12] The most common side effects are joint and muscle pain in the arms or legs. [13]
Osteoporosis can affect nearly 1 in 3 women and the bone loss is the most rapid within the first 2–3 years after menopause. This can be prevented by menopause hormone therapy or MHT, which is meant to prevent bone loss and the degradation of the bone microarchitecture and is noted to reduce the risk of fractures in bones by 20-30%.
Osteochondroma is the most common benign tumor of bone. [1] [2] The tumors take the form of cartilage-capped bony projections or outgrowth on the surface of bones ().[3] [4] It is characterized as a type of overgrowth that can occur in any bone where cartilage forms bone.